Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Kemp

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Dialogues in Clinical Neuroscience|August 12, 2008
Bipolar depression: trial-based insights to guide patient careDavid E Kemp, David J Muzina, Roger S McIntyre, et al.
Current Psychiatry Reports|September 30, 2010
Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanismsJun Chen, Yiru Fang, David E Kemp, et al.
Neuropsychiatric Disease and Treatment|March 21, 2009
Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studiesPrashant Gajwani, David J Muzina, David E Kemp, et al.
The Journal of Clinical Psychiatry|April 5, 2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidoneDavid E Kemp, Ellyn Johnson, Wei V Wang, et al.
Clinical Therapeutics|December 20, 2011
Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentaryRenrong Wu, David E Kemp, Martha Sajatovic, et al.
Journal of Clinical Psychopharmacology|March 18, 2008
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic reviewKeming Gao, David E Kemp, Stephen J Ganocy, et al.
Current Psychiatry Reports|November 11, 2006
Acute treatment of mania: an update on new medicationsPrashant Gajwani, David E Kemp, David J Muzina, et al.
Journal of Clinical Psychopharmacology|September 16, 2010
Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010)David E Kemp, James M Eudicone, Robert D McQuade, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 20, 2007
Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisiaDavid E Kemp, William S Gilmer, Jenelle Fleck, et al.
The Journal of Clinical Psychiatry|January 24, 2008
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolenceKeming Gao, Stephen J Ganocy, Prashant Gajwani, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Dialogues in Clinical Neuroscience|August 12, 2008
Bipolar depression: trial-based insights to guide patient careDavid E Kemp, David J Muzina, Roger S McIntyre, et al.
Current Psychiatry Reports|September 30, 2010
Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanismsJun Chen, Yiru Fang, David E Kemp, et al.
Neuropsychiatric Disease and Treatment|March 21, 2009
Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studiesPrashant Gajwani, David J Muzina, David E Kemp, et al.
The Journal of Clinical Psychiatry|April 5, 2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidoneDavid E Kemp, Ellyn Johnson, Wei V Wang, et al.
Clinical Therapeutics|December 20, 2011
Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentaryRenrong Wu, David E Kemp, Martha Sajatovic, et al.
Journal of Clinical Psychopharmacology|March 18, 2008
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic reviewKeming Gao, David E Kemp, Stephen J Ganocy, et al.
Current Psychiatry Reports|November 11, 2006
Acute treatment of mania: an update on new medicationsPrashant Gajwani, David E Kemp, David J Muzina, et al.
Journal of Clinical Psychopharmacology|September 16, 2010
Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010)David E Kemp, James M Eudicone, Robert D McQuade, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 20, 2007
Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisiaDavid E Kemp, William S Gilmer, Jenelle Fleck, et al.
The Journal of Clinical Psychiatry|January 24, 2008
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolenceKeming Gao, Stephen J Ganocy, Prashant Gajwani, et al.
Pageof 7